NASDAQ · ORKA
Oruka Therapeutics, Inc.
$95.48-$1.18 (-1.22%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.35% below the high.
Loading market information…
NASDAQ · LUMO · USD
Stock price, earnings
Quote as of Dec 11, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lumos Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lumos Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 | May 3, 2023 | -$0.89+20.54% vs estimate | $691.00K+283.89% vs estimate |
|---|
| Q4 2022 | Mar 1, 2023 | -$0.98-3.16% vs estimate | $512.00K+347.81% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$95.48-$1.18 (-1.22%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.35% below the high.
$3.61-$0.05 (-1.23%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.01% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
$2.93-$0.05 (-1.68%)
Cerecor Inc.’s quoted price sits in the lower half of its reported 52-week range, 1.68% below the high.
$7.56+$0.29 (+3.99%)
Eyenovia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.94% below the high.
$1.10$0.00 (0.0%)
Satsuma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.39% below the high.
$1.91-$0.04 (-1.8%)
Grace Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.22% below the high.
